Clinical trial · Observational
HIPEC in Ovarian Cancer, Case-Controls Study With 10-years Follow up
HIPEC in Ovarian Cancer: The First Case Control Study in Mexican Patients With 10-year Follow-up
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objectives: Compare overall survival (OS) and progression-free survival (PFS) among ovarian cancer patients who underwent into cytoreduction and HIPEC procedure vs patients who only received systemic chemotherapy in a 10-years follow up of a case-control study Methods: Cases were defined as patients treated by cytoreduction and HIPEC, and were matched (1:2) with patients treated with chemotherapy only, defined as controls. PFS and OS in the two groups were measured and compared. PFS was calculated from initiation of treatment to progression, death or to the last known follow-up. OS was calculated from initiation of treatment to death or to the last known follow-up.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HIPEC | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cytoreduction and HIPEC | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- HIPEC
- description
- women, with ovarian cancer stage III-IV or recurrent with carcinomatosis treated with cytoreduction and HIPEC
- interventionNames
- Procedure: cytoreduction and HIPEC
- label
- No HIPEC
- description
- women, with ovarian cancer stage III-IV or recurrent with carcinomatosis, treated with systemic chemotherapy only
Primary outcomes (2)
- measure
- free overall survival
- timeFrame
- 10 years
- description
- survillance from HIPEC procedure/IV chemotherapy for carcinomatosis, to death date or last consultation (months) Kaplan Meier curve
- measure
- free recurrence survival
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 72 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of Epithelial ovarian cancer confirmed * FIGO stage III-IV or carcinomatosis recurrence * No comorbidities or controlled comorbidities * ECOG 0-2 Exclusion Criteria: * without carcinomatosis
References
Publications (0)
Data not yet available